Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Viracept nelfinavir: Phase II data; Marketed

Agouron said that in a study of 195 patients who had previously failed nucleoside analog therapy, 67 percent

Read the full 186 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE